NCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
Clinical Trials
21 trialsNCT05027386 2026-02-05
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06592287 2024-09-19
The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT05924997 2024-02-21
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05742750 2023-02-24
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05559008 2022-11-09
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
Phase 1/2 Unknown
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04476459 2021-03-15
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sun Yat-sen University
Phase 1/2 Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown
NCT04572542 2020-10-01
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
The First Affiliated Hospital of Xiamen University
Phase 1/2 Unknown
NCT04446091 2020-06-24
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT04202978 2020-04-16
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
Zhongshan Hospital Xiamen University
Phase 1/2 Unknown
NCT04286711 2020-02-27
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
China Medical University, China
Phase 1/2 Unknown
NCT04182724 2019-12-03
Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04133337 2019-10-21
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 1/2 Unknown
NCT04035876 2019-07-29
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
Phase 1/2 Unknown
NCT03654612 2018-10-18
Y-HR2017-025
China International Medical Foundation
Phase 1/2 Unknown
NCT02942329 2018-02-26
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03201146 2017-11-17
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
West China Hospital
Phase 1/2 Unknown
NCT02772029 2016-05-13
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Unknown
NCT02727309 2016-04-04
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Peking University Cancer Hospital & Institute
Phase 1/2 Unknown